David Greenberg is the Chairman of Pediatrics and the director of the Pediatric Infectious Disease Unit of the Soroka University Medical Center, Beer-Sheva, Israel. He is a Professor of Pediatrics and Infectious Diseases at the Ben-Gurion University of the Negev, Israel. Prof. Greenberg obtained his MD degree in 1991 from the Ben-Gurion University of the Negev. He was boarded in Pediatrics in 1996. From 1997 to 1999 he performed a fellowship in Pediatric Infectious Diseases at the British Columbia Children’s Hospital and University of British Columbia, Vancouver B.C. Canada. Upon his return he joined the department of Pediatrics and Pediatric Infectious Disease Unit at the Soroka University Medical Center as a pediatrician and consultant in Pediatrics ID. He is also a senior attending pediatrics at the Pediatric Department. Prof. Greenberg acts as a pediatric infectious diseases consultant for the southern district of the Israel General Health Insurance.
Prof. Greenberg is a member of the Israel National Vaccine and Infectious Disease Advisory Board for the Israeli ministry of health office. Prof. Greenberg was the chairman of the Israeli Pediatric Infectious Disease Society 2014-2017. He served as the chairman of the Israel Clinical Pediatrics Society from 2007 to 2011. Between 2007-2009, he served as the medical manager of the renowned center for severely disabled young adults “ALEH Negev”.
Prof. Greenberg is the founder and serves as the medical director of several companies, such as Advanced Inhalation Therapies-AIT LTd. and ENOX Biopharma and holds several patents in the field of diagnostics and treatment of infectious diseases. On the international level, Prof. Greenberg is a member of the WHO’s Pneumonia Vaccine Trial Investigators Group. He was a board member of ESPID’s educational committee 2012-2016. Together with European researchers he is a member of the community-acquired pneumonia pediatric research initiative consortium (CAP-PRI). He is a “Professor Onorific” of Transylvania university of Brasov, Romania. In the last 10 years, Prof. Greenberg has received research grants from, acts as a consultant for, and served on scientific boards of several large pharmaceutical companies such as MSD, GSK, Pfizer, Astra Zeneca and Abbvie as well as with the American Center of Disease Control and Prevention (CDC).
He has contributed over 200 peer-reviewed articles, review articles and book chapters both in local and international scientific publications.
Dr. Greenberg’s research activities focus on the epidemiology, diagnosis, prevention and treatment of respiratory infections and in particular of community-acquired pneumonia; pneumococcal vaccines and the spread of antibiotic-resistant pneumococci in the community; invasive infections including bacteremia and meningitis; viral respiratory infections and their interaction with bacterial infection in community-acquired pneumonia.